Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a healthy financial status and stable track record that earned trust from its employees and shareholders. Bukwang’s operating profit is at the top of the rank in the industry, nearing 20% as of financial year 2014. Bukwang’s armamentarium consists of more than 100 products in various therapeutic areas: liver disease treatments such as Levovir and Legalon, diabetic complication products such as Dexid and Thioctacid, CNS disorder drugs including Lonasen, Ixel and Orfil, and respiratory disease treatments such as Azeptin and Asima. Bukwang continues to grow its original drug business through consistent focus on new drug development.